Frequency of Epstein Barr virus infection among Sudanese children patients with Burkitt’s lymphoma
Keywords:Frequency, Epstein barr virus, Burkitt's lymphoma, Immunohistochemistry test
Background: Burkitt's lymphoma (BL) is a B-cell malignancy categorized in three forms endemic, sporadic, and immunodeficiency-associated variants. Epstein barr virus (EBV) is associated with BL in almost all African populations. The frequency of EBV associated with BL is unknown in Sudan. The study aimed to estimate the frequency of EBV in Sudanese patients with BL.
Methods: The study was a descriptive cross-sectional study conducted between June 2014 and July 2019 in 34 paraffin-embedded tissue sections obtained from diagnosed BL patients attending Soba university hospital in Khartoum city (Sudan). Monoclonal IgG1 antibody was used to detect EPV by immunohistochemistry technique.
Results: The study showed that 44.1% (15/34) of BL patients were positive for EBV, whereas 55.9% (19/34) showed negative EBV. Males, 66.7% (10/15) were more affected by the EBV infection than females, 33.3% (5/15). P value=0.014.
Conclusions: Despite BL is considered a rare type of lymphoma in Sudan; the obtained results showed a lower frequency of EBV compared with other studies worldwide.
Klein E, Klein G. Burkitt lymphoma. Semina Canc Biol. 2009;19(6):345-6.
Jaffe ES, Harris NL, Stein H. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. World Health Organization Classification of Tumours.
Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol. 2012;156:744-756
Bench AJ, Erber WN, Follows GA, Scott MA. Molecular genetic analysis of haematological malignancies II: Mature lymphoid neoplasms. Int J Laborat Hematol. 2007;29(4):229-60.
Ferry JA. Burkitt's lymphoma: clinicopathologic features and differential diagnosis. Oncologist. 2006;11:375-83.
Ok CY, Li L, Young KH. EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. Exp Mol Med. 2015;47:132.
Williams. H, Crawford. D. H. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood. 2006;107:862-9.
Grömminger S, Mautner J, Bornkamm GW. Burkitt lymphoma: the role of Epstein‐Barr virus revisited. Brit J Haematol. 2012;156(6):719-29.
Kelly GL, Rickinson AB. Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program. 2007:277-84.
Bellan C, Lazzi S, Hummel M, Palummo N, De Santi M, Amato T, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood. 2005;106(3):1031-6.
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844-7.
Graham BS, Lynch DT. Burkitt Lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan- https://www.ncbi.nlm.nih.gov/books/NBK538148.
Chene A, Donati D, Guerreiro-Cascais AO, Levitsky V, Chen Q, Falk KI, et al. A molecular link between malaria and Epstein–Barr virus reactivation. PLoS Pathog. 2007;3:80.
Pannone G, Zamparese R, Pace M, Pedicillo MC, Cagiano S, Somma P, et al. The role of EBV in the pathogenesis of Burkitt’s Lymphoma: an Italian hospital based survey. Infect Aen Canc. 2014;9(1):34.
Parviz D. Study of EBV expression in BL by PCR and ISH in IRAN May. Dent Res J. 2014;11(3):380-5
Queiroga EM, Gualco G, Weiss LM, Dittmer DP, Araujo I, Klumb CE, et al. Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features. Am J Clinic Pathol. 2008;130(6):946-56.
Yousif IB, Yousif YM, AbdElaziz MS. LMP-1 Immunohistochemistry Detection of Epstein- Barr Virus In Lymphoma Among Sudanese Patients. Int J Res. 2015;3(9):63-9.